Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease
06 janv. 2022 08h30 HE
|
Vaxcyte, Inc.
-- Company Expects to Deliver Topline Immunogenicity Results from the Phase 1/2 Clinical Study by End of 2022 -- -- VAX-24 is a 24-Valent Pneumococcal Conjugate Vaccine Candidate Designed to Provide...
Vaxcyte to Present at Upcoming Investor Conferences
11 nov. 2021 16h05 HE
|
Vaxcyte, Inc.
FOSTER CITY, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines...
Vaxcyte Reports Third Quarter 2021 Financial Results and Provides Business Update
10 nov. 2021 16h10 HE
|
Vaxcyte, Inc.
-- Company Expects to Submit VAX-24 IND Application to FDA in Q1 2022 -- -- Completed Manufacture of VAX-24 GMP Drug Product and GLP Toxicology Study -- FOSTER CITY, Calif., Nov. 10, 2021 (GLOBE...
Vaxcyte Appoints Carlos Paya and Michael Kamarck to Its Board of Directors
28 oct. 2021 08h30 HE
|
Vaxcyte, Inc.
FOSTER CITY, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines...
Vaxcyte to Present at Guggenheim 2nd Annual Vaccine and Infectious Disease Conference
28 sept. 2021 16h05 HE
|
Vaxcyte, Inc.
FOSTER CITY, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines...
Vaxcyte to Present at 2021 Cantor Virtual Global Healthcare Conference
21 sept. 2021 16h01 HE
|
Vaxcyte, Inc.
FOSTER CITY, Calif., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines...
Vaxcyte Appoints Annie Drapeau and Teri Loxam to Its Board of Directors
20 sept. 2021 16h30 HE
|
Vaxcyte, Inc.
FOSTER CITY, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines...
Vaxcyte Reports Second Quarter 2021 Financial Results and Provides Business Update
11 août 2021 16h07 HE
|
Vaxcyte, Inc.
FOSTER CITY, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines...
Vaxcyte Announces Expanded CARB-X Award to Advance Development of VAX-A1, a Vaccine to Prevent Group A Streptococcus Infections
05 août 2021 08h30 HE
|
Vaxcyte, Inc.
-- Award Commits an Additional $3.2 Million in Funding; Total Potential Funding of $29.7 Million Based on Future Milestones -- -- Vaxcyte Plans to Initiate IND-Enabling Studies for VAX-A1 in Second...
Vaxcyte to Present at the Jefferies Virtual Healthcare Conference
27 mai 2021 16h05 HE
|
Vaxcyte, Inc.
FOSTER CITY, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines...